Date issuedProductSafety information
8/26/2019 soliqua (lixisenatide /insuline glargin) soliqua

(lixisenatide /insuline glargin):  Important information on dosing.CLICK HERE​​​

8/26/2019 Advaquin ( levofloxacin)

Advaquin ( levofloxacin): Risk of aortic aneurysm and dissection.CLICK HERE​​​

7/1/2019 Darzalex (Daratumumab)

Darzalex (Daratumumab): New identified risk of hepatitis B reactivation.CLICK HERE​​​

6/27/2019 Lemtrada® Alemtuzumab

Alemtuzumab (Lemtrada): New safety information.CLICK HERE​​

6/12/2019 Apixaban, Edoxaban, Dabigatran and Rivaroxaban

Direct Healthcare Professional Communication (DHPC) for the Direct Oral Anticoagulants (DOACs) Apixaban, Edoxaban, Dabigatran and Rivaroxaban.CLICK HERE​​

5/7/2019 blinatumomab

​Blincyto (pembrolizumab): Risk of Medication Errors and Benzyl alcohol toxicity​.CLICK HERE​

5/6/2019 Jectin-12® (Cyanocobalamin)

Cyanocobalamin and the risk of medication error.CLICK HERE​​

5/6/2019 Xeljanz® (Tofacitinib)

Increased risk of pulmonary embolism and overall mortality with higher dose of XELJANZ (tofacitinib) for rheumatoid arthritis.CLICK HERE​​

4/29/2019 Genvoya ® (elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide)

Increased risk of treatment failure and increased risk of mother-to-child transmission of HIV infection due to lower exposure of elvitegravir and cobicistat during the second and third trimesters of pregnancy.CLICK HERE​​​

4/15/2019 Dapagliflozin

Risk of Fournier’s gangrene (necrotising fasciitis of the perineum) with Sodium-glucose-Co-Transporter 2 inhibitors (SGLT2i).CLICK HERE​​